Comparative Benchmarking
In the context of the broader market, RGNT competes directly with industry leaders such as NCEL and ZYBT. With a market capitalization of $19.53M, it holds a significant position in the sector. When comparing efficiency, RGNT's gross margin of N/A stands against NCEL's N/A and ZYBT's 20.51%. Such benchmarking helps identify whether Regentis Biomaterials Ltd is trading at a premium or discount relative to its financial performance.
